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A randomised controlled trial evaluating the effectiveness and tolerability 
of step-up and step-down varenicline therapy for smoking cessation: Study 
protocol 
 
Drovandi A, Teague P, Glass B and Malau-Aduli B 
ABSTRACT 
Background: Varenicline remains the most effective medication for smoking cessation, however 
discontinuation as a result of adverse events negatively impacts medication adherence, and the 
likelihood of a quit attempt being successful. Post treatment cravings and withdrawal symptoms 
may also occur, increasing the likelihood of treatment failure, due to lapse and relapse after 
achieving initial abstinence. This protocol details a trial investigating changes in the effectiveness 
and tolerability of varenicline, when an extended step-up and step-down regimen are used. 
Methods: A phase 4, randomised, double-blinded, placebo-controlled single-centre study with a 
treatment period of 16 weeks, and follow-up period of 12 weeks will be conducted. Up to 201 
participants will be enrolled and allocated in a 1:1:1 ratio to a placebo-matching control group, 
step-up, or step-down intervention group, all receiving behavioural counselling and quitting advice. 
Participants will be contacted weekly during treatment and fortnightly during follow-up. Eligible 
participants are smokers over 18 years old, willing to quit smoking, are able to attend clinic visits, 
and have no uncontrolled or serious medical issues. Primary outcome measures are comparisons 
of biochemically confirmed continuous abstinence rates, 7-day point prevalence abstinence rates 
and the frequency, severity and duration of adverse events, cravings and withdrawal symptoms. 
Secondary outcome measures are participant adherence to the study medication throughout 
treatment, and comparisons of changes in smoking satisfaction and reward. Effects of each regimen 
on smoking cessation will be assessed by logistic regression, with survival analyses used for a more 
precise estimate of when cessation occurs. Primary endpoints will then be compared using a 
general linear model. Australian New Zealand Clinical Trials Registry: ACTRN12616000802404p 
 
INTRODUCTION 
Tobacco use continues to be a major contributor to preventable morbidity and mortality, being 
strongly linked to a growing list of health conditions, including several forms of cancer, and 
cardiovascular and respiratory diseases (Fiore et al., 2008). Unfortunately, successful smoking 
cessation continues to be challenging, despite the availability of smoking cessation medications and 
behavioural counselling techniques (Cahill et al., 2013). Medications such as varenicline (Champix® 
/ Chantix®), the most effective agent available for smoking cessation (Cahill et al., 2016), have 
several clinical issues impacting on their effectiveness such as causing intolerable adverse effects 
leading to premature therapy discontinuation, poor adherence, and a resurgence of cravings and 
withdrawal symptoms after therapy has been completed (Drovandi et al., 2016; Balmford et al., 
2011; Catz et al., 2011; Liberman et al., 2013; Rigotti et al., 2010). 
Modifications to the varenicline regimen through changes in daily dosing may address these 
problems as suggested by a recent systematic review (Drovandi et al., 2017). Modifications trialled 
and warranting further study include the use of an extended duration of pre-quit varenicline 
therapy (Hajek et al., 2011; Hawk et al., 2012), and an extended duration of varenicline therapy 
(Tonstad et al., 2006; Williams et al., 2007). These modifications were theorised to reduce the 
frequency and severity of adverse events at the beginning of therapy and the long-term risk of 
relapse at the end of treatment. A modification yet to be tested is a step-down period at the end 
of varenicline therapy, potentially reducing the short-term risk of relapse at the end of treatment, 
which has been encountered in some clinical trials (Tonstad et al., 2006; Rigotti et al., 2010). 
This protocol was developed to evaluate changes in the effectiveness and tolerability of varenicline, 
when it is introduced more slowly over a period of 4 weeks and ceased over a period of 2 weeks. It 
is proposed that the use of extended ‘step-up’ therapy will reduce the frequency and severity of 
adverse effects, which are usually more prominent at the beginning of therapy (Tonstad et al., 2016; 
Williams et al., 2007), and the use of ‘step-down’ therapy will reduce the likelihood of recurring 
cravings and withdrawal symptoms due to a sudden drop in dopamine levels from the removal of 
varenicline (Coe et al., 2005). 
METHODS 
This protocol has been registered with the Australian New Zealand Clinical Trials Registry 
(ACTRN12616000802404p), and was developed to comply with the Helsinki Declaration of 1975 
(revised in 2008) and Australian Guidelines on the development of ethical research. Ethical approval 
was given by the James Cook University’s Human Research Ethics Committee (approval number 
H6748). This article for the study protocol follows the Standard Protocol Items: Recommendations 
for Interventional Trials (SPIRIT) checklist (Chan et al., 2013).   
Study Design 
A randomised, double-blinded, placebo-controlled trial will consist of three treatment groups with 
different dosing schedules: two intervention groups (step-up and step-down varenicline therapies) 
and a placebo-matched control group. This community-based single-site trial will require 
participants to adhere to a treatment duration of 16-weeks and a follow-up duration of 12-weeks, 
and attend scheduled clinic visits at James Cook University’s Health Clinic in Townsville, Australia.  
Participant Eligibility and Recruitment 
Eligible participants are required to be at least 18 years old and motivated to quit smoking, have a 
Fagerström Test for Nicotine Dependence (FTND) score of at least 5.0, indicate their intention to 
comply with scheduled clinic visits, have no history of major or uncontrolled depressive or other 
psychiatric disorders, and use appropriate hormonal contraception if a woman of childbearing age. 
Participants are ineligible if they have a history of a suicide attempt or any suicidal behaviours in 
the previous 2 years, have a severe or uncontrolled major depressive, psychiatric, or cardiovascular 
disorder, have a current psychosis, have concomitant substance abuse disorders, have used 
varenicline within the previous 6 months, or do not agree to abstain from non-cigarette tobacco 
products during the intervention and follow-up periods. 
Participants will be recruited from pharmacies, general practitioner clinics and newspaper 
advertisements in Townsville, Australia. Potential participants may view, self-assess and complete 
an expression of interest flyer at these locations, which include preliminary eligibility questions, and 
the contact details of the principal investigator to facilitate a baseline visit with the potential 
participant. Final eligibility and further information and consent documents will be provided during 
the baseline visit to ensure the eligibility and safety of participants. 
Treatment Groups and Interventions 
The dose regimens for all the treatment groups are detailed in Table 1. Intervention group 1 (step-
up) will be assigned to take 0.5mg once daily for 7 days, 0.5mg twice daily for 7 days, 0.5mg once 
daily plus 1.0mg once daily for 7 days, 1.0mg twice daily for 11 weeks, then 2 weeks of placebo 
tablets matched to the step-down intervention group. Intervention group 2 (step-down) will be 
assigned to take 2 weeks of placebo tablets matched to the step-up intervention group, followed 
by 0.5mg once daily for 3 days, 0.5mg twice daily for 4 days, 1.0mg twice daily for 11 weeks, then 
0.5mg twice daily for 7 days, then 0.5mg once daily for 7 days. The control group will be assigned 
to take 2 weeks of placebo tablets matched to the step-up intervention group, followed by 0.5mg 
once daily for 3 days, 0.5mg twice daily for 4 days, 1.0mg twice daily for 11 weeks, then 2 weeks of 
placebo tablets matched to the step-down intervention group. The medication provided will be 
supplied in a dose administration aid (DAA) to avoid dosing confusion, maintain treatment blinding, 
and to serve as a mechanism for monitoring participant adherence (Haywood and Glass, 2016). 
Eligible participants will be randomly assigned a participant identifier number (PIN), each of which 
is linked through a computer-generated randomisation sequence to a treatment group. Treatment 
allocations will be sealed in individual envelopes, and a research associate who is not involved in 
the study will be responsible for affixing PINs to each DAA to ensure continued double-blinding. 
However, a participant’s allocated treatment can be revealed prior to completion of the study, if 
the participant experiences a life-threatening or other severe event. 
Interventions for eligible participants for the duration of the trial, including data collection tools are 
detailed in Tables 2 and 3 for the treatment and follow-up periods respectively. Participants will be 
contacted weekly during the treatment phase, and fortnightly during the follow-up phase through 
a combination of telephone calls and face to face clinic visits. These scheduled interactions will 
gather data on participant health indicators (both physical and mental), concomitant medication 
load, adverse events, cravings and withdrawal symptoms experienced, and recent smoking habits. 
Participants will receive a booklet on smoking cessation during the baseline visit, and up to 10 
minutes of individualised counselling on techniques for smoking cessation during each intervention, 
and be recommended to set a quit date between weeks 4 and 6 of treatment.  
Study Outcomes 
Primary outcomes to be assessed during this trial are comparisons of biochemically confirmed 
continuous abstinence rates, 7-day point prevalence abstinence rates and the frequency, severity, 
and duration of adverse effects, cravings, and withdrawal symptoms. These primary outcomes will 
determine if step-up or step-down varenicline dosing has positive effects as measured by improved 
smoking cessation rates and reduced adverse events, cravings, or withdrawal symptoms during 
cessation attempts. Secondary outcome measures include adherence to the study medication 
throughout treatment and changes in smoking satisfaction and reward. 
Data Collection and Management 
During the interventional and follow-up periods, as detailed in Table 2 and Table 3 respectively, 
data for the primary and secondary outcomes will be initially collected from participants on a 
weekly basis, with monthly face to face clinic visits being interspersed by telephone calls. Adverse 
events. Continuous and 7-day point prevalence abstinence rates will be assessed by multiple 
methods, including the Nicotine Use Inventory (NUI), a personal smoking log, and biochemically 
confirmed using a Micro+ Smokerlyzer device. The NUI will be administered during scheduled 
telephone and clinic visits by the principal investigator, querying the participants’ use of cigarettes 
or any other nicotine-containing products. The smoking log will be used daily by participants to 
track their exposure to nicotine throughout the treatment and follow-up periods, and reported 
abstinence to be confirmed during clinic visits using a Micro+ Smokerlyzer device, with a cut-off 
reading of <10ppm considered as being abstinent. All adverse events, including serious and non-
serious, will be recorded on case report forms on a per-participant basis, to be reported to the 
principal investigator, and causality determined during the scheduled telephone and face to face 
clinic visits. Participants will be encouraged to log adverse events daily as they occur, ensuring to 
note changes in severity or apparent cause if they persist over several days, will be coded using 
MedDRA, and followed-up until cessation of the event. Concerning or unusual adverse events will 
be reported immediately to the principal investigator, with events considered to be serious or 
unexpected to also be reported to Pfizer Inc., the approving ethics committee, and the Adverse 
Drug Reaction unit of the Therapeutic Goods Administration. Physical health will be assessed at the 
commencement and cessation of treatment, and at the completion of the follow-up period, and 
include recording of participant height, weight, and vital signs (blood pressure, respiratory rate, and 
heart rate). Mental health will be assessed initially using the Suicide Behaviours Questionnaire 
Revised (SBQ-R) (Osman et al., 2001), and monitored fortnightly using the Patient Health 
Questionnaire-9 (PHQ-9) (Kroenke et al., 2001). The 9-item version of the Minnesota Nicotine 
Withdrawal Scale (MNWS) (Hughes and Hatsukami, 1986) will be used to assess weekly changes in 
cravings and withdrawal symptoms, using a 5-point Likert scale ranging from 0 (not at all) to 5 
(extreme). The MNWS will be self-administered by participants on a daily basis, and reported to the 
principal investigator during phone calls and clinic visits. 
Medication adherence checks will be done by the principal investigator during the treatment period 
clinic visits, by counting remaining tablets in returned DAAs. Changes in smoking satisfaction and 
reward will be assessed by the principal investigator using the Modified Cigarette Evaluation 
Questionnaire (mCEQ) (Cappelleri et al., 2007), a 12-item questionnaire rating on a 7-point scale 
from 1 (Not at all) to 7 (Extremely) the common experiences normally received by smoking. All data 
collection will be performed by the principal investigator only, who will personally enter all data 
into a master excel spreadsheet, which will be stored on a passwordprotected computer in the 
office of the principal investigator. PINs will be used in this spreadsheet to ensure confidentiality.  
Sample Size and Statistical Analyses 
Using GPOWER v3.1, it was determined that to detect a moderate effect size with 80% power, a 
total of 119 completers are required for statistical power for the primary endpoints of the study, 
being the biochemically confirmed continuous abstinence rate for participants in each treatment 
group. To ensure statistical power is achieved, up to 201 participants will be enrolled to 
accommodate up to 40% participant withdrawal from treatment and loss to follow-up as 
demonstrated by similarly designed smoking cessation trials (Hajek et al., 2011; Rigotti et al., 2010; 
Hawk et al., 2012). Intention to treat analysis will include univariate and multivariate analysis of the 
factors associated with abstinence post-quit date. Analysis will occur after the final participant has 
completed their end-of-study clinic visit. 
Data analysis will include assessing biochemically confirmed continuous abstinence rates and the 
presence of, and numerical scale of severity of adverse events, cravings and withdrawal symptoms, 
for smokers or non-smokers. Quantitative data will be subjected to multivariate analysis in SPSS 
(v23) to establish relationship between categorical and continuous variables. Logistic regression will 
be used to assess the effect of the treatment regimens on smoking cessation. Odds ratio (OR) will 
be used to compare the relative odds of occurrence of smoking cessation, between the active and 
control groups. The 95% confidence intervals (CI) will be used to estimate the precision of the OR. 
Survival analysis (via cox regression) will be used to measure more precise and absolute estimates 
of when smoking cessation occurs. A survival probability estimate will also be calculated using the 
Kaplan-Meier method. Survival curves and a non-parametric statistical log rank test will be used to 
determine significant differences between the groups. The severity of adverse events, cravings and 
withdrawal symptoms will be compared between the three groups, using a General Linear Model 
(GLM) in SPSS (v23). Significance levels were set at 0.05 and a medium effect size as reported by 
Cohen (1988) will be calculated to determine the magnitude of statistically significant relationships. 
No interim analyses are planned for this study. 
 
Study Monitoring 
Adverse event-recording documents will be provided both electronically and as hard-copies during 
clinic visits, and when additionally requested. Participants who experience intolerable adverse 
events or worsening of concomitant medical conditions may have their dose temporarily reduced 
or withdrawn, with recommencing of the standard dose at the discretion of the participant, 
principal investigator, and medical advisor. Participants may also have treatment permanently 
withdrawn if their participation places them at an excessive risk of harm (including changes in 
behaviour or mood), or demonstrate an inability to comply with the study protocol. Participants 
will be encouraged to log adverse events daily, which will be regularly monitored by the principal 
investigator, to track event progression and ensure the resolution of events. 
ETHICS AND DISSEMINATION 
This research has been approved by the James Cook University Human Research Ethics Committee 
(approval number H6748), with amendments to the protocol submitted to the committee and to 
Pfizer Inc. as they occur. The principal investigator will be responsible for gaining informed consent 
from participants and will maintain patient confidentiality during clinic visits and phone calls. 
Advisors to the principal investigator will only have access to de-identified data from participants.  
Results for this research will largely be disseminated through publication in peer-reviewed journals. 
The approving ethics committee, Pfizer Inc., and the supplier of the dose administration aids 
(Webstercare) will be provided with detailed reports on the outcomes of the research, and 
participants will be offered a report of the research if desired.  
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Table 1. Varenicline dosing schedules for the three treatment regimens. 
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Group 




































for 3 days, 
0.5mg twice 




















for 3 days, 
0.5mg twice 











* Only 0.5mg-tablet matching placebos will used during the study 
 
 
Table 2. Schedule of procedures between the principal investigator and study participants during the treatment period. 
BL: Baseline     CV: Clinic Visit     TC: Telephone Call     EOI: Expression of Interest     FTND: Fagerström Test for Nicotine Dependence     SBQ-R: Suicide Behaviours Questionnaire Revised     PIN: Participant Identifier Number     
PHQ-9: Patient Health Questionnaire-9     NUI: Nicotine Use Inventory     mCEQ: Modified cigarette evaluation questionnaire     MNWS: Minnesota Nicotine Withdrawal Scale     
Participant Activity Screening BL Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 Week 10 Week 11 Week 12 Week 13 Week 14 Week 15 Week 16 
Window 2 weeks - ± 2 days ± 2 days ± 2 days ± 2 days ± 2 days ± 2 days ± 2 days ± 2 days ± 2 days ± 2 days ± 2 days ± 2 days ± 2 days ± 2 days ± 2 days ± 2 days 
Interaction Type - CV TC TC TC CV TC TC TC CV TC TC TC CV TC TC TC CV 
EOI Flyer X                  
Participant 
Information 
X X                 
Risks and Benefits X X                 
Informed Consent X X                 
Medical History  X                 
FTND  X                 
SBQ-R  X                 
Baseline Details 
Demographics 
 X                 
Smoking history  X                 
Carbon Monoxide 
Test  
 X    X    X    X    X 
Height/weight  X                X 
Vitals  X                X 
Randomisation  X                 
PIN assigned  X                 
PHQ-9  X  X  X  X  X  X  X  X  X 
NUI   X X X X X X X X X X X X X X X X 
Concomitant 
Medications 
 X X X X X X X X X X X X X X X X X 
Study Drug 
Provided 
 X    X    X    X     
mCEQ  X X X X X X X X X X X X X X X X X 
Adverse Events  X X X X X X X X X X X X X X X X X 
MNWS  X X X X X X X X X X X X X X X X X 
Counselling (<10 
minutes) 
 X X X X X X X X X X X X X X X X X 
‘Quit Because You 
Can’ Booklet 
 X                 
Adherence 
Recording 
     X    X    X    X 
Smoking Log  X X X X X X X           
Table 3. Schedule of procedures between the principal investigator and participants during the 
follow-up period 
Participant Activity Week 17 Week 18 Week 19 Week 20 Week 21 Week 22 Week 23 Week 24 Week 25 Week 26 Week 27 Week 28 
Window ± 2 days ± 2 days ± 2 days ± 2 days ± 2 days ± 2 days ± 2 days ± 2 days ± 2 days ± 2 days ± 2 days ± 2 days 
Interaction Type N/A TC N/A TC N/A CV N/A TC N/A TC N/A CV 
Carbon  
Monoxide Test  
 
    X      X 
Height/weight            X 
Vitals            X 
PHQ-9  X  X  X  X  X  X 




X  X  X  X  X  X 
mCEQ  X  X  X  X  X  X 
Adverse Events  X  X         
MNWS  X  X  X  X  X  X 
Counselling 
 (<10 minutes) 
 
X  X  X  X  X  X 
CV: Clinic Visit     TC: Telephone Call     PHQ-9: Patient Health Questionnaire-9 NUI: Nicotine Use Inventory               
mCEQ: Modified cigarette evaluation questionnaire     MNWS: Minnesota Nicotine Withdrawal Scale      
